However, veliparib, another PARP inhibitor which was evaluated in combination with chemotherapy in first-line ovarian cancer, used a threshold score of ≥33 after retrospective analysis of this cutoff in triple negative breast cancer, and demonstrated increased sensitivity [109, 110]. Here, PARP1 is linked to ovarian carcinoma.